ATTBF

Abattis Bioceuticals Corp.

 
Ordinary Shares International Reporting
OTCQB
Verified Company Profile 10/09/2017
Contact Info
  • Suite 224
  • 970 Burrard Street
  • Vancouver, BC V6Z 2R4
  • Canada

Business Description


 
Financial Reporting/Disclosure
Reporting Status International Reporting: Canadian Securities Exchange
Audited Financials Audited
Latest Report Jun 30, 2017 Interim Financial Report
CIK 0001515768
Fiscal Year End 9/30
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2833 - Medicinal and botanicals
Incorporated In: British Columbia, Canada
Year of Inc. 1997
Employees Not Available
Company Officers/Contacts
Robert Abenante CEO, President
Shuang Xie CTO
Rene David COO
Anthony Jackson CFO
Christina Boddy Corporate Secretary
Michael Bluestein Securities Counsel
Company Directors
Robert Abenante
Rene David
Peter Gordon
James Irving Independent Director, Audit Committee Member
William Panenka Independent Director
Shuang Xie
Service Providers
Accounting/Auditing Firm
Dale Matheson Carr-Hilton Labonte LLP
1140 West Pender St.
Suite 1500 and 1700
Vancouver, BC, V6E 4G1
Canada
 
Securities Counsel Investor Relations Firm

Not Available
Company History
  • Formerly=Abattis Biologix Corp. until 9-2012
ATTBF Security Details
Share Structure
Market Value1 $28,823,812 a/o Nov 17, 2017
Authorized Shares Unlimited a/o Oct 08, 2017
Outstanding Shares 167,580,301 a/o Oct 08, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 91,134,125 a/o Sep 06, 2016
Par Value Not Available
Transfer Agent(s)
Computershare
Shareholders
Shareholders of Record 199 a/o Sep 06, 2016
Non US Stock Exchange Listing
ATT - Canadian Securities Exchange - Qualified
Short Selling Data
Short Interest 3,577 (-84.58%)
Oct 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security